Karol Watson

Lipid lowering in high-risk populations: how low should we go?

Therapeutic lifestyle changes for hypertension and cardiovascular risk reduction.

Plasma lipoprotein concentrations in ethnic populations.

Lessons learned from recent lipid-lowering trials: why physicians should change clinical practice.

Atherosclerosis in type 2 diabetes mellitus: the role of insulin resistance.

Surgical risk in patients with metabolic syndrome: focus on lipids and hypertension.

Managing cardiometabolic risk: an evolving approach to patient care.

Quality indicators for the care of ischemic heart disease in vulnerable elders.

Cardiovascular risk reduction among African Americans: a call to action.

What is the evidence in favor of low-dose statin therapy in 2008?

Acculturation is associated with left ventricular mass in a multiethnic sample: the Multi-Ethnic Study of Atherosclerosis.

The 2013 ACC/AHA Cholesterol Treatment Guidelines: Applicability to Patients with Diabetes.

Slippery Slope of Triglycerides: They Are Associated With Risk, But in the Statin Era, Does Targeting Them Confer Benefit?

MY APPROACH to the Patient With Memory Loss Who Needs a Statin.

Neighborhoods and racial/ethnic differences in ideal cardiovascular health (the Multi-Ethnic Study of Atherosclerosis).

Triglycerides: A reappraisal.

Closing the Remaining Evidence Gap: Randomized Controlled Trial Data to Support Statin Therapy for Low-Density Lipoprotein ≥190 mg/dL.